A YEAR LIKE NO OTHER
THE MICHAEL J . FOX FOUNDATION 2023 YEAR IN REVIEW
A Year Like No Other : A Message from MJFF Leadership
Nearly 200 active trials testing different therapies . Sixteen therapeutics targeting the pathology of alpha-synuclein , known to be linked to Parkinson ’ s , in human trials . More than 88 Phase II and 37 Phase III active clinical trials .
This is today ’ s Parkinson ’ s drug development pipeline — historically robust , and crackling with activity .
What ’ s more , the pipeline just got an enormous boost on a scale never seen before in Parkinson ’ s research . The new biomarker validated in April of this year , the so-called alpha-synuclein seeding amplification assay ( aSyn-SAA ), which detects the misfolded alpha-synuclein protein , makes it possible for the first time to confirm Parkinson ’ s biologically , in living people , even before symptoms begin .
The Michael J . Fox Foundation has been relentlessly pursuing a Parkinson ’ s biomarker since our earliest days because of its game-changing capacity to unlock and accelerate the promise of more targeted treatments for all stages of the disease , earlier intervention and potentially even prevention . Biomarkers transform clinical trial design and smooth the path to regulatory
2